Olympus Partners has $ 4 billion to invest after the intermediate market capital company completed fundraising for its last flagship fund. The company said on Wednesday that its eighth swimming pool arrived at $ 3.5 billionAnd jumped at $ 4 billion with the inclusion of co-investments in its LPS and the reinvestments expected, according to a letter of March 26 to Olympus investors. Olympus had set a hard ceiling of $ 4 billion for the VIII fund, the maximum that the fund was authorized to cover investors.
Olympus spent about a year in marketing for its eighth swimming pool, which increased 15% more than its previous fund. Olympus Growth Fund VII collection $ 3.04 billion at the end of 2017.
Earlier this month, Fortune reported that the Olympus VIII fund had lifted $ 2.87 billion.
Olympus is the EP company of the President and CEO Rob Morris, which is also its founder. The company is investing in commercial services, food services, consumer products, health services, financial services, industrial services and manufacturing. Since its launch in 1988, Olympus has raised $ 12 billion in capital. The company has also returned $ 6 billion to investors in the past three years, including $ 3 billion in 2024, Fortune has reported.
Morris, in the letter, discussed the Trump administration’s pricing policy, which caused the volatility of the stock market markets and the fears of a recession. Morris said that capital-investment managers should do their best to avoid the “incoming missiles” of the prices. For companies with a strongly dependent supply chain, he advised to diversify safer geographies or pursue exempt tariff alternatives. “There are many other tactical movements, but no infallible plan to completely avoid the economic storm, a trade war could ignite,” wrote Morris in the letter.
The VIII Fund has started to invest in January and has so far carried out two transactions. In January, Olympus acquired Acceleration, a supplier of infrastructure products and services on the data centers market, for $ 455 million. PE also picked up a manufacturer of generic drugs PAI Pharma For $ 605 million in February. Transactions were “the fastest Olympus bought two investments from the advent of a fund,” according to the letter.
This story was initially presented on Fortune.com
